Login Register Cart 0
Generic placeholder image

Current Computer-Aided Drug Design

Editor-in-Chief

ISSN (Print): 1573-4099
ISSN (Online): 1875-6697

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

In silico Approach and Molecular Docking Studies of Potent Bioactive Compounds of Carica papaya as Anti-breast Cancer Agents

Author(s): V.L. Maruthanila, Ramakrishnan Elancheran and Sankaran Mirunalini*

Volume 18, Issue 3, 2022

Published on: 05 August, 2022

Page: [196 - 212] Pages: 17

DOI: 10.2174/1573409918666220519112027

Price: $65

Abstract

Background: Breast cancer is one of the greatest global dilemmas, and the current treatment option is to target hormone receptors with partial agonists/antagonists. Estrogen and aromatase enzymes play important roles in breast cancer. Excessive estrogen activity or inadequate estrogen production leads to various hormonal issues, including breast cancer. Potent breast cancer drugs are Tamoxifen, Paclitaxel, Cyclophosphamide, Trastuzumab, etc., and aromatase inhibitors, include Anastrozole, Letrozole, and Exemestane, etc. In general, breast cancer drugs cause numerous adverse effects in humans.

Objectives: This study has attempted to identify alternative drug candidates from Carica papaya for treating breast cancer with fewer side effects.

Methods: To achieve this, we have utilized computational methods to predict the characteristics of bioactive compounds from Carica papaya and determine the target binding affinities using the Schrödinger suite (Maestro 9.5). The target protein and ligands were obtained from the well-known database. Carica papaya has 35 identified bioactive compounds that were drawn using ChemDraw software and performed Ligand preparation wizard. Absorption, Distribution, Metabolism, and Excretion (ADME) analysis is performed with QikProp.

Results: From the docking studies, the phytocompounds such as Chlorogenic acid, Myricetin, Quercetin, Isorhamnetin, and Catechin showed the highest Glide scores (G Score). Among the five bioactive phytocompounds, Chlorogenic acid has a higher G Score with good binding energy than Tamoxifen, Anastrozole, and Letrozole standards. The pharmacokinetic properties and drug-likeness of phytocompounds were determined using ADME profiling.

Conclusion: Carica papaya phytocompounds serve as an antiestrogen or aromatase inhibitor that regulates estrogen levels to reduce the risk of breast cancer in postmenopausal women. As a result, we recommend that these top five bioactive phytocompounds be investigated further in in vitro and in vivo studies.

Keywords: Carica papaya, phenolic acids, estrogen receptor, aromatase enzyme, apoptosis, maestro 9.5.

« Previous Next »
Graphical Abstract

[1]
Acharya, R.; Chacko, S.; Bose, P.; Lapenna, A.; Pattanayak, S.P. Structure based multitargeted molecular docking analysis of selected furanocoumarins against breast cancer. Sci. Rep., 2019, 9(1), 15743.
[http://dx.doi.org/10.1038/s41598-019-52162-0] [PMID: 31673107]
[2]
Maruthanila, V.L.; Elancheran, R.; Kunnumakkara, A.B.; Kabilan, S.; Kotoky, J. Recent development of targeted approaches for the treat-ment of breast cancer. Breast Cancer, 2017, 24(2), 191-219.
[http://dx.doi.org/10.1007/s12282-016-0732-1] [PMID: 27796923]
[3]
Khalil, S.; Hatch, L.; Price, C.R.; Palakurty, S.H.; Simoneit, E.; Radisic, A.; Pargas, A.; Shetty, I.; Lyman, M.; Couchot, P.; Roetzheim, R. Addressing breast cancer screening disparities among uninsured and insured patients: A student-run free clinic initiative. J. Community Health, 2019, 1-5.
[PMID: 31667647]
[4]
Sudha, A.; Srinivasan, P.; Kanimozhi, V.; Palanivel, K.; Kadalmani, B. Antiproliferative and apoptosis-induction studies of 5-hydroxy 3′,4′,7-trimethoxyflavone in human breast cancer cells MCF-7: An in vitro and in silico approach. J. Recept. Signal Transduct. Res., 2018, 38(3), 179-190.
[http://dx.doi.org/10.1080/10799893.2018.1468780] [PMID: 29734849]
[5]
Ross, J.A.; Kasum, C.M. Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 2002, 22(1), 19-34.
[http://dx.doi.org/10.1146/annurev.nutr.22.111401.144957] [PMID: 12055336]
[6]
Voskresensky, O.N.; Levitsky, A.P. QSAR aspects of flavonoids as a plentiful source of new drugs. Curr. Med. Chem., 2002, 9(14), 1367-1383.
[http://dx.doi.org/10.2174/0929867023369790] [PMID: 12132993]
[7]
Maruthanila, V.L.; Elancheran, R.; Mirunalini, S. Carica papaya leaves and cancer prevention: An overview. Mini Rev. Med. Chem., 2020.
[http://dx.doi.org/10.2174/1389557520666200811102622]
[8]
Maruthanila, V.L.; Elancheran, R.; Roy, N.K.; Bhattacharya, A.; Kunnumakkara, A.B.; Kabilan, S.; Kotoky, J. in silico molecular modeling of selected natural ligands and their binding features with estrogen receptor alpha. Curr. Comput. Aided. Drug Des., 2019, 15(1), 89-96.
[PMID: 30306879]
[9]
Sharma, D.; Kumar, S.; Narasimhan, B. Estrogen alpha receptor antagonists for the treatment of breast cancer: A review. Chem. Cent. J., 2018, 12(1), 107.
[http://dx.doi.org/10.1186/s13065-018-0472-8] [PMID: 30361894]
[10]
Chellam, J.; Rohini Deepa, I. Computational biological study of aromatase inhibitors docking with human placental aromatase cytochrome P450. Int. J. Pharm. Pharm. Sci., 2016, 8(7), 93-97.
[11]
van Duursen, M.B.M. Modulation of estrogen synthesis and metabolism by phytoestrogens in vitro and the implications for women’s health. Toxicol. Res. (Camb.), 2017, 6(6), 772-794.
[http://dx.doi.org/10.1039/c7tx00184c] [PMID: 30090542]
[12]
Suvannang, N.; Nantasenamat, C.; Isarankura-Na-Ayudhya, C.; Prachayasittikul, V. Molecular docking of aromatase inhibitors. Molecules, 2011, 16(5), 3597-3617.
[http://dx.doi.org/10.3390/molecules16053597]
[13]
Goodman, A. Extended letrozole after 5 years of tamoxifen adds benefits in hormone-receptor positive breast cancer, is cost-effective. Oncol. Times., 2006, 28(1), 6-8.
[http://dx.doi.org/10.1097/01.COT.0000289796.64219.5c]
[14]
Smyth, L.; Hudis, C. Adjuvant hormonal therapy in premenopausal women with breast cancer. Indian J. Med. Paediatr. Oncol., 2015, 36(4), 195-200.
[http://dx.doi.org/10.4103/0971-5851.171530] [PMID: 26811586]
[15]
El Sayed, R.; El Jamal, L.; El Iskandarani, S.; Kort, J.; Abdelsalam, M.; Assi, H.I. Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: Sequencing treatment and overcoming resistance. Front. Oncol., 2019, 9, 510.
[http://dx.doi.org/10.3389/fonc.2019.00510] [PMID: 31281796]
[16]
Fabian, C.J. The what, why and how of aromatase inhibitors: Hormonal agents for treatment and prevention of breast cancer. Int. J. Clin. Pract., 2007, 61(12), 2051-2063.
[http://dx.doi.org/10.1111/j.1742-1241.2007.01587.x] [PMID: 17892469]
[17]
Elancheran, R.; Saravanan, K.; Divakar, S.; Kumari, S.; Maruthanila, V.L.; Kabilan, S.; Ramanathan, M.; Devi, R.; Kotoky, J. Design, syn-thesis and biological evaluation of novel 1, 3-thiazolidine-2, 4-diones as anti-prostate cancer agents. Anticancer. Agents Med. Chem., 2017, 17(13), 1756-1768.
[PMID: 28403781]
[18]
Ng, H.W.; Zhang, W.; Shu, M.; Luo, H.; Ge, W.; Perkins, R.; Tong, W.; Hong, H. Competitive molecular docking approach for predicting estrogen receptor subtype α agonists and antagonists. BMC Bioinformatics, 2014, 15(11)(Suppl. 11), S4.
[http://dx.doi.org/10.1186/1471-2105-15-S11-S4] [PMID: 25349983]
[19]
Singh, P.; Bast, F. Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and andro-gen receptor; in silico and in vitro. Invest. New Drugs, 2015, 33(3), 575-593.
[http://dx.doi.org/10.1007/s10637-015-0240-8] [PMID: 25895100]
[20]
Larocca, L.M.; Teofili, L.; Maggiano, N.; Piantelli, M.; Ranelletti, F.O.; Leone, G. Quercetin and the growth of leukemic progenitors. Leuk. Lymphoma, 1996, 23(1-2), 49-53.
[http://dx.doi.org/10.3109/10428199609054801] [PMID: 9021685]
[21]
Li, X.Y.; He, B.F.; Luo, H.J.; Huang, N.Y.; Deng, W.Q. 3-Acyl-5-hydroxybenzofuran derivatives as potential anti-estrogen breast cancer agents: A combined experimental and theoretical investigation. Bioorg. Med. Chem. Lett., 2013, 23(16), 4617-4621.
[http://dx.doi.org/10.1016/j.bmcl.2013.06.022] [PMID: 23830503]
[22]
Shtaiwi, A.; Adnan, R.; Khairuddean, M.; Khan, S.U. Computational investigations of the binding mechanism of novel benzophenone imine inhibitors for the treatment of breast cancer. RSC Advances, 2019, 9(61), 35401-35416.
[http://dx.doi.org/10.1039/C9RA04759J]
[23]
Zhang, F.; Zhai, T.; Haider, S.; Liu, Y.; Huang, Z.J. Synergistic effect of chlorogenic acid and caffeic acid with fosfomycin on growth inhibi-tion of a resistant Listeria monocytogenes strain. ACS Omega, 2020, 5(13), 7537-7544.
[http://dx.doi.org/10.1021/acsomega.0c00352] [PMID: 32280897]

Rights & Permissions Print Cite
Article Metrics
50
4
© 2024 Bentham Science Publishers | Privacy Policy